Cargando…

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

BACKGROUND: Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. METHODS: We conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradenas, Edwards, Trinité, Benjamin, Urrea, Víctor, Marfil, Silvia, Ávila-Nieto, Carlos, Rodríguez de la Concepción, María Luisa, Tarrés-Freixas, Ferran, Pérez-Yanes, Silvia, Rovirosa, Carla, Ainsua-Enrich, Erola, Rodon, Jordi, Vergara-Alert, Júlia, Segalés, Joaquim, Guallar, Victor, Valencia, Alfonso, Izquierdo-Useros, Nuria, Paredes, Roger, Mateu, Lourdes, Chamorro, Anna, Massanella, Marta, Carrillo, Jorge, Clotet, Bonaventura, Blanco, Julià
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847406/
https://www.ncbi.nlm.nih.gov/pubmed/33554155
http://dx.doi.org/10.1016/j.medj.2021.01.005
_version_ 1783644927523028992
author Pradenas, Edwards
Trinité, Benjamin
Urrea, Víctor
Marfil, Silvia
Ávila-Nieto, Carlos
Rodríguez de la Concepción, María Luisa
Tarrés-Freixas, Ferran
Pérez-Yanes, Silvia
Rovirosa, Carla
Ainsua-Enrich, Erola
Rodon, Jordi
Vergara-Alert, Júlia
Segalés, Joaquim
Guallar, Victor
Valencia, Alfonso
Izquierdo-Useros, Nuria
Paredes, Roger
Mateu, Lourdes
Chamorro, Anna
Massanella, Marta
Carrillo, Jorge
Clotet, Bonaventura
Blanco, Julià
author_facet Pradenas, Edwards
Trinité, Benjamin
Urrea, Víctor
Marfil, Silvia
Ávila-Nieto, Carlos
Rodríguez de la Concepción, María Luisa
Tarrés-Freixas, Ferran
Pérez-Yanes, Silvia
Rovirosa, Carla
Ainsua-Enrich, Erola
Rodon, Jordi
Vergara-Alert, Júlia
Segalés, Joaquim
Guallar, Victor
Valencia, Alfonso
Izquierdo-Useros, Nuria
Paredes, Roger
Mateu, Lourdes
Chamorro, Anna
Massanella, Marta
Carrillo, Jorge
Clotet, Bonaventura
Blanco, Julià
author_sort Pradenas, Edwards
collection PubMed
description BACKGROUND: Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. METHODS: We conducted a longitudinal analysis on a prospective cohort of COVID-19 patients followed up for >6 months. Neutralizing activity was evaluated using HIV reporter pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody titer was evaluated by ELISA against the S2 subunit, the receptor binding domain (RBD), and the nucleoprotein (NP). Statistical analyses were carried out using mixed-effects models. FINDINGS: We found that individuals with mild or asymptomatic infection experienced an insignificant decay in neutralizing activity, which persisted 6 months after symptom onset or diagnosis. Hospitalized individuals showed higher neutralizing titers, which decreased following a 2-phase pattern, with an initial rapid decline that significantly slowed after day 80. Despite this initial decay, neutralizing activity at 6 months remained higher among hospitalized individuals compared to mild symptomatic. The slow decline in neutralizing activity at mid-term contrasted with the steep slope of anti-RBD, S2, or NP antibody titers, all of them showing a constant decline over the follow-up period. CONCLUSIONS: Our results reinforce the hypothesis that the quality of the neutralizing immune response against SARS-CoV-2 evolves over the post-convalescent stage. FUNDING: This study was funded by 10.13039/501100016387Grifols, the Departament de Salut of the Generalitat de Catalunya (grant nos. SLD016 to J.B. and SLD015 to J.C.), the Spanish Health Institute Carlos III (grant nos. PI17/01518 and PI18/01332 to J.C.), CERCA Programme/Generalitat de Catalunya2017 SGR 252, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat, and Correos. The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript. E.P. was supported by a doctoral grant from the National Agency for Research and Development of Chile (ANID; 72180406). C.A.-N. was supported by a doctoral grant from Generalitat de Catalunya and Fons Social Europeu (FI). S.P.-Y. was supported by 10.13039/501100011850Fundación Canaria Doctor Manuel Morales and 10.13039/100015528Universidad de La Laguna.
format Online
Article
Text
id pubmed-7847406
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78474062021-02-01 Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes Pradenas, Edwards Trinité, Benjamin Urrea, Víctor Marfil, Silvia Ávila-Nieto, Carlos Rodríguez de la Concepción, María Luisa Tarrés-Freixas, Ferran Pérez-Yanes, Silvia Rovirosa, Carla Ainsua-Enrich, Erola Rodon, Jordi Vergara-Alert, Júlia Segalés, Joaquim Guallar, Victor Valencia, Alfonso Izquierdo-Useros, Nuria Paredes, Roger Mateu, Lourdes Chamorro, Anna Massanella, Marta Carrillo, Jorge Clotet, Bonaventura Blanco, Julià Med (N Y) Clinical and Translational Report BACKGROUND: Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. METHODS: We conducted a longitudinal analysis on a prospective cohort of COVID-19 patients followed up for >6 months. Neutralizing activity was evaluated using HIV reporter pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody titer was evaluated by ELISA against the S2 subunit, the receptor binding domain (RBD), and the nucleoprotein (NP). Statistical analyses were carried out using mixed-effects models. FINDINGS: We found that individuals with mild or asymptomatic infection experienced an insignificant decay in neutralizing activity, which persisted 6 months after symptom onset or diagnosis. Hospitalized individuals showed higher neutralizing titers, which decreased following a 2-phase pattern, with an initial rapid decline that significantly slowed after day 80. Despite this initial decay, neutralizing activity at 6 months remained higher among hospitalized individuals compared to mild symptomatic. The slow decline in neutralizing activity at mid-term contrasted with the steep slope of anti-RBD, S2, or NP antibody titers, all of them showing a constant decline over the follow-up period. CONCLUSIONS: Our results reinforce the hypothesis that the quality of the neutralizing immune response against SARS-CoV-2 evolves over the post-convalescent stage. FUNDING: This study was funded by 10.13039/501100016387Grifols, the Departament de Salut of the Generalitat de Catalunya (grant nos. SLD016 to J.B. and SLD015 to J.C.), the Spanish Health Institute Carlos III (grant nos. PI17/01518 and PI18/01332 to J.C.), CERCA Programme/Generalitat de Catalunya2017 SGR 252, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat, and Correos. The funders had no role in the study design, the data collection and analysis, the decision to publish, or the preparation of the manuscript. E.P. was supported by a doctoral grant from the National Agency for Research and Development of Chile (ANID; 72180406). C.A.-N. was supported by a doctoral grant from Generalitat de Catalunya and Fons Social Europeu (FI). S.P.-Y. was supported by 10.13039/501100011850Fundación Canaria Doctor Manuel Morales and 10.13039/100015528Universidad de La Laguna. Elsevier Inc. 2021-03-12 2021-01-31 /pmc/articles/PMC7847406/ /pubmed/33554155 http://dx.doi.org/10.1016/j.medj.2021.01.005 Text en © 2021 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Clinical and Translational Report
Pradenas, Edwards
Trinité, Benjamin
Urrea, Víctor
Marfil, Silvia
Ávila-Nieto, Carlos
Rodríguez de la Concepción, María Luisa
Tarrés-Freixas, Ferran
Pérez-Yanes, Silvia
Rovirosa, Carla
Ainsua-Enrich, Erola
Rodon, Jordi
Vergara-Alert, Júlia
Segalés, Joaquim
Guallar, Victor
Valencia, Alfonso
Izquierdo-Useros, Nuria
Paredes, Roger
Mateu, Lourdes
Chamorro, Anna
Massanella, Marta
Carrillo, Jorge
Clotet, Bonaventura
Blanco, Julià
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
title Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
title_full Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
title_fullStr Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
title_full_unstemmed Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
title_short Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
title_sort stable neutralizing antibody levels 6 months after mild and severe covid-19 episodes
topic Clinical and Translational Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847406/
https://www.ncbi.nlm.nih.gov/pubmed/33554155
http://dx.doi.org/10.1016/j.medj.2021.01.005
work_keys_str_mv AT pradenasedwards stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT trinitebenjamin stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT urreavictor stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT marfilsilvia stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT avilanietocarlos stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT rodriguezdelaconcepcionmarialuisa stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT tarresfreixasferran stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT perezyanessilvia stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT rovirosacarla stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT ainsuaenricherola stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT rodonjordi stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT vergaraalertjulia stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT segalesjoaquim stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT guallarvictor stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT valenciaalfonso stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT izquierdouserosnuria stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT paredesroger stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT mateulourdes stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT chamorroanna stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT massanellamarta stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT carrillojorge stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT clotetbonaventura stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes
AT blancojulia stableneutralizingantibodylevels6monthsaftermildandseverecovid19episodes